CCRM Fertility

Strategic and capital allocation decisions sit with the board, led by majority investor TA Associates since their 2021 acquisition. Clinical and laboratory standards remain under Dr. William Schoolcraft's purview as medical director, while day-to-day operational leadership is executed by a CEO and a regional management structure. This creates a dual authority: TA Associates controls the growth strategy and M&A, while Schoolcraft oversees the core clinical IP.

TA Associates acquired a majority interest in CCRM in 2021, transitioning the firm from a physician-owned partnership to an institutionally backed platform. Dr. Schoolcraft and other partner physicians retained significant minority equity, aligning their interests with the sponsor's hold period. The transaction provided a liquidity event for founding partners while capitalizing further de novo clinic builds and tuck-in acquisitions.

CCRM pursues a two-pronged expansion: building wholly owned, ground-up clinics especially in high-barrier urban markets like Toronto's Yorkville, and selectively acquiring existing fertility practices where physician-leaders agree to adopt CCRM's proprietary lab protocols. The firm does not operate a loose franchise model — every location eventually migrates to CCRM's central lab quality system and single-embryo transfer guidelines.

CCRM's core intellectual property lies in its embryology lab protocols, including a proprietary blastocyst culture medium and refined cryopreservation techniques developed by Dr. Schoolcraft's team. Unlike chains that acquire clinics and leave local labs intact, CCRM requires each hub to run on its standardized laboratory operating procedures and quality benchmarks, an integration path that limits acquisition targets but aims to preserve outcome consistency.

CCRM's model is anchored in brick-and-mortar labs and in-person clinical visits, with satellite offices offering telehealth for initial consultations. In 2023 it expanded its employer benefits partnerships to serve as a designated in-network provider for large self-insured employers through Progyny and similar platforms. However, it has not launched a standalone digital health app, distinguishing it from benefits-only fertility players.